Locally Advanced. Vascular Involvement. What These Words Actually Mean.

“Locally advanced” pancreatic cancer means the tumour has not spread to distant organs, but it does involve nearby structures — most often one of three major blood vessels: the superior mesenteric artery (SMA), the portal vein, or the coeliac axis. Whether that involvement rules out surgery depends on which vessel, how much of it is involved, and what a surgical team is equipped to do about it.

Vein involvement (portal vein) is treated very differently from artery involvement (SMA, coeliac axis). At a high-volume pancreatic surgery centre, reconstructing a vein — removing the affected segment and rebuilding it — is a routine part of the operation, not an exceptional one. Artery involvement is more technically demanding, but is not automatically disqualifying either; it depends on the extent of involvement and the surgical team’s experience with vascular reconstruction.

The label on a radiology report describes anatomy. Whether that anatomy is operable is a judgment call — and judgment calls differ between centres, especially at this level of complexity.

A resectability opinion is not fixed the day it’s given. Three things can change it:

The imaging itself. Not every scan is read to the same standard. Reviewing the same imaging with fresh eyes — particularly the specific slices around the vessel in question — sometimes changes the read.

Response to chemotherapy. Chemotherapy given before surgery (neoadjuvant treatment) can shrink a tumour enough to convert a borderline or locally advanced case into an operable one. In one published trial of neoadjuvant chemotherapy for borderline-resectable pancreatic cancer, 79% of patients went on to surgery and 86% of those achieved clear (R0) margins — compared with 58% in earlier historical data. If you’ve had chemotherapy since your last resectability opinion, that alone is a reason to have your current imaging looked at again.

Who is doing the assessment. Outcomes in pancreatic surgery track closely with how often a team operates. Prof. Büchler performs 600–800 pancreatic operations a year, including a high proportion involving vascular resection and reconstruction — routine work at this volume, not exceptional. A different team, operating far less often, will reasonably draw the line between “operable” and “not operable” in a different place.

You may also be reading about treatments that target a tumour where it sits — various forms of localised or ablative therapy, still under active clinical study for pancreatic cancer. These are a different category of treatment from surgical removal, and one does not substitute for the other.

A “locally advanced” label does not, by itself, mean surgery is off the table, and it does not mean a local (non-surgical) therapy is now your only option either. Both are possibilities. The determination of which applies to your case comes from a specialist review of your current imaging — not from the label alone.

Whether a tumour can be surgically removed is not only relevant to the operation itself. A growing number of post-surgery treatment approaches — currently under study, including immunotherapy trials — are only available to patients whose disease was resectable in the first place.

One early-phase study at Johns Hopkins, published in Nature Communications (10 February 2026), followed 12 resected pancreatic cancer patients given a personalised vaccine after surgery: 11 of 12 developed an immune (T-cell) response, and 4 of 12 remained disease-free at a median follow-up of 35.8 months. This is early-stage, ongoing research — Prof. Büchler’s practice does not offer or administer this vaccine, and this is not a claim about your own outcome. It illustrates a broader point: being a surgical candidate is the entry requirement for a wider set of options, not a consolation compared to newer drug therapies. It’s usually the more consequential question, not the smaller one.